ArticleJournal of animal science2025
Insulin-sensitizing effects of fibroblast growth factor-21 in underfed sheep.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reversal of insulin resistance by fibroblast growth factor-21(FGF21) in rodent and non-human primate models of obesity and in well-fed (WF) sheep was associated with increased production of the insulin-sensitizing hormone adiponectin. In contrast, FGF21 therapy failed to increase plasma adiponectin and improve insulin action in energy-deficient ruminants facing metabolically demanding states such as early lactation dairy cows. The goal of the study was to test the hypothesis that FGF21 is unable to improve insulin action in energy-deficient ruminants as a consequence of its failure to increase plasma adiponectin. Non-pregnant, non-lactating ewes were treated for 12 d with FGF21 or excipient when WF (2-fold of maintenance energy requirement, n = 4) or underfed (UF; 0.5-fold of maintenance energy requirement, n = 4). Plasma variables were measured as indices of insulin action (glucose, insulin, and adiponectin), lipolysis (fatty acids), and ketogenesis (β-hydroxybutyrate) on days 1, 4, 7, 10, and 12 of treatment. The effect of treatments on insulin action was assessed by measuring glucose disposal during insulin tolerance tests on day 10 and glucose tolerance tests on day 11. Quantitative RT-PCR was used to measure expression of genes mediating FGF21 effects in adipose tissue. Underfed ewes lost weight (energy balance, EB, P < 0.01) and had reduced plasma glucose (EB, P = 0.04) and insulin (EB × Day, P = 0.01), confirming negative EB. In UF ewes, FGF21 retained the ability to reduce plasma glucose (FGF21, P = 0.02) but not plasma insulin. FGF21 improved insulin action in both WF and UF ewes during glucose (insulin response area; FGF21, P = 0.02) and insulin tolerance tests (FGF21, P = 0.04) and did so in the absence of increased plasma adiponectin in UF ewes. Underfeeding reduced adipose tissue expression of the FGF21 co-receptor β-Klotho (EB, P < 0.01) and attenuated FGF21 stimulation of the FGF-responsive genes SPRY4 (EB × FGF21, P = 0.07) and DUSP4 (EB × FGF21, P = 0.02). FGF21 failed to increase adiponectin mRNA expression at both feeding levels. FGF21 had no effect on plasma fatty acids but reduced plasma β-hydroxybutyrate in UF ewes (EB × FGF21, P = 0.02). These data show that energy insufficiency alone does not prevent FGF21 improvement of insulin action in ruminants and that increased adiponectin production is not necessary for FGF21 insulin-sensitizing effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.